Market Overview

A Data-Rich Year Has Analysts Accepting Their Fate Therapeutics Trade

Share:

Wedbush reiterated its Outperform rating on Fate Therapeutics Inc (NASDAQ: FATE), saying the company is executing well on advancing its early stage cell therapy pipeline into patients, with significant data catalysts expected later this year.

The comments came after Fate announced earlier this week the clearance by FDA of an IND for NK100 and the near-term start of an open-label Ph 1 study in lymphodepleted adult r/r AML patients at the University of Minnesota (UMN) following IRB approval.

“IND cleared for NK100, expecting Ph 1 study in advanced AML to begin shortly; we expect to see superior results compared to past NK-based therapeutic efforts,” analyst David Nierengarten wrote in a note.

Other catalysts are studies of NK100 in solid tumors and combination studies with approved mAbs set to start later this year and the recently announced iPSC-derived NK cell candidate could be advanced to clinic in next 12 months. In addition, the company’s lead ProTmune program on track to enter Ph 2 by mid-year.

Shares of Fate Therapeutics closed Thursday at $4.64. The analyst has a price target of $7.

Related:

Carl Icahn's Track Record In Big Pharma

Bill Ackman Is Out Of Valeant

Latest Ratings for FATE

DateFirmActionFromTo
Aug 2020Cantor FitzgeraldMaintainsOverweight
May 2020HC Wainwright & Co.Initiates Coverage OnBuy
May 2020BMO CapitalMaintainsMarket Perform

View More Analyst Ratings for FATE
View the Latest Analyst Ratings

 

Related Articles (FATE)

View Comments and Join the Discussion!

Posted-In: David Nierengarten WedbushAnalyst Color Price Target Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com